Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), and connected persons, rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Share Sale Price: £14.55 per Ordinary Share and $44.03 per American Depositary Share (ADS).
- Transaction Date: March 1, 2013.
- Purpose: To meet tax liabilities following the vesting of awards granted in 2010 under the GlaxoSmithKline Share Value Plan.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details changes in shareholdings for specific individuals:
- Mr. P. Thomson: Sold 436 Ordinary Shares; retained 401 Ordinary Shares.
- Dr. M. Slaoui (Executive Director): Sold 230 ADS; retained 410 ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Checklist
- Verify the total number of shares sold by PDMRs and connected persons to assess insider sentiment.
- Confirm the share price of £14.55/$44.03 against market data for March 1, 2013.
- Review the company's annual report (Form 20-F) for comprehensive financial metrics not included in this 6-K.